EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Susceptibility profile and β-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam—SMART 2016–21

James A Karlowsky, Sibylle H Lob, Mark A Estabrook, Fakhar Siddiqui, C Andrew DeRyke, Katherine Young, Mary R Motyl, Daniel F Sahm

JAC-Antimicrobial Resistance · 03.05.2023 · 5 (3)

DOI: 10.1093/jacamr/dlad080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 28.06.2023. Verfasst von James A Karlowsky und 7 weiteren Autor:innen. Beteiligte Einrichtung: IHMA, Inc., Schaumburg, IL, USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp & Dohme LLC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To determine susceptibility profiles and β-lactamase content for ceftolozane/tazobactam-resistant and imipenem/relebactam-resistant Pseudomonas aeruginosa isolates collected in eight global regions during 2016–21.

Methods

Broth microdilution MICs were interpreted using CLSI breakpoints. PCR to identify β-lactamase genes or WGS was performed on selected isolate subsets.

Results

Ceftolozane/tazobactam-resistant [from 0.6% (Australia/New Zealand) to 16.7% (Eastern Europe)] and imipenem/relebactam-resistant [from 1.3% (Australia/New Zealand) to 13.6% (Latin America)] P. aeruginosa varied by geographical region. Globally, 5.9% of isolates were both ceftolozane/tazobactam resistant and imipenem/relebactam resistant; 76% of these isolates carried MBLs. Most ceftolozane/tazobactam-resistant/imipenem/relebactam-susceptible isolates carried ESBLs (44%) or did not carry non-intrinsic (acquired) β-lactamases (49%); 95% of imipenem/relebactam-resistant/ceftolozane/tazobactam-susceptible isolates did not carry non-intrinsic β-lactamases. Isolates that carried indicators of strong PDC (Pseudomonas-derived cephalosporinase) up-regulation without a mutation known to expand the spectrum of PDC, or non-intrinsic β-lactamases, showed an 8-fold increase in ceftolozane/tazobactam modal MIC; however, this rarely (3%) resulted in ceftolozane/tazobactam resistance. Isolates with a PDC mutation and an indicator for PDC upregulation were ceftolozane/tazobactam non-susceptible (MIC, ≥ 8 mg/L). MICs ranged widely (1 to >32 mg/L) for isolates with a PDC mutation and no positively identified indicator for PDC up-regulation. Imipenem/relebactam-resistant/ceftolozane/tazobactam-susceptible isolates without non-intrinsic β-lactamases frequently (91%) harboured genetic lesions implying OprD loss of function; however, this finding alone did not account for this phenotype. Among imipenem-non-susceptible isolates without non-intrinsic β-lactamases, implied OprD loss only shifted the distribution of imipenem/relebactam MICs up by 1–2 doubling dilutions, resulting in ∼10% imipenem/relebactam-resistant isolates.

Conclusions

P. aeruginosa with ceftolozane/tazobactam-resistant/imipenem/relebactam-susceptible and imipenem/relebactam-resistant/ceftolozane/tazobactam-susceptible phenotypes were uncommon and harboured diverse resistance determinants.

Autor:innen und Institutionen

  • IHMA, Inc., Schaumburg, IL, USA.
  • Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Merck & Co., Inc., Rahway, NJ, USA.

Förderung

  • Merck Sharp & Dohme LLC

Zitieren

APA

Karlowsky, J. A., Lob, S. H., Estabrook, M. A., Siddiqui, F., DeRyke, C. A., Young, K., Motyl, M. R., & Sahm, D. F. (2023). Susceptibility profile and β-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam—SMART 2016–21. JAC-Antimicrobial Resistance, 5(3). https://doi.org/10.1093/jacamr/dlad080

Vancouver

Karlowsky JA, Lob SH, Estabrook MA, Siddiqui F, DeRyke CA, Young K, et al. Susceptibility profile and β-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam—SMART 2016–21. JAC-Antimicrobial Resistance. 2023;5(3). doi:10.1093/jacamr/dlad080

BibTeX
@article{Karlowsky2023,
  author = {Karlowsky, James A and Lob, Sibylle H and Estabrook, Mark A and Siddiqui, Fakhar and DeRyke, C Andrew and Young, Katherine and Motyl, Mary R and Sahm, Daniel F},
  title = {Susceptibility profile and β-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam—SMART 2016–21},
  journal = {JAC-Antimicrobial Resistance},
  year = {2023},
  volume = {5},
  number = {3},
  doi = {10.1093/jacamr/dlad080}
}
Kostenlos starten →